DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study
DON 在小儿脑型疟疾中的应用:I/II 期剂量递增安全性研究
基本信息
- 批准号:10458716
- 负责人:
- 金额:$ 119.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:5 year oldAdultAdverse eventAffectAfrica South of the SaharaAfricanAnimal ModelAnimalsAntimalarialsAreaBiological MarkersBlood - brain barrier anatomyBrain EdemaCerebral MalariaCerebrovascular CirculationCessation of lifeChildChildhoodClinicalClinical TrialsComaCommunicable DiseasesCountryDataDiagnosisDiseaseDoseDouble-Blind MethodDrug KineticsEconomicsElectroencephalogramEnrollmentEvaluationFutureGlutamineGoalsHistopathologyHospitalsHumanInfectionInterventionIntravenousMagnetic Resonance ImagingMalariaMedical StaffMorbidity - disease rateMouse StrainsMusNeurologicNorleucineOutcomeParasitemiaParticipantPathologicPatientsPediatric cohortPersonsPhasePhysiologicalPlacebo ControlPlacebosPlasmodium bergheiPlasmodium falciparumPopulationProcessPublic HealthPublishingRandomizedResearchRisk FactorsSafetySerious Adverse EventSupportive careSurvivorsSyndromeTarget PopulationsTestingTherapeutic InterventionTimeToxic effectTrainingVulnerable Populationsantagonistanti-cancerbasebrain magnetic resonance imagingbrain volumecandidate markerclinical efficacydisabilitydrug discoveryefficacy studyexperienceimprovedimproved outcomemalaria infectionmortalitymouse modelpatient populationpre-clinicalpreclinical studyprimary outcomeradiological imagingsafety studyscale uptumor
项目摘要
Project Summary/Abstract
Cerebral malaria (CM) is defined as an otherwise unexplained coma in a patient with Plasmodium falciparum
parasitemia. The condition is common, primarily affects African children less than five years old, and has a
large public health impact in endemic areas. Of the ~350,000 children diagnosed annually with CM, 15% die
and 30% of survivors have neurological abnormalities at the time of hospital discharge. The mainstay of
treatment is intravenous antimalarial drugs and supportive care. No adjunctive therapy has previously been
proven effective in decreasing the high rates of mortality and morbidity in this condition. Our long-term goal is
to establish feasible therapies that decrease death and disability rates in this vulnerable population.
We will investigate 6-diazo-5-oxo-L-norleucine (DON), a glutamine antagonist, as a candidate adjunctive
therapy for pediatric CM. We identified DON through a rational drug discovery process and tested its efficacy
in several pre-clinical studies. Mice with experimental CM have radiographic and pathological abnormalities
similar to those seen in human pediatric CM; DON administered to mice that are severely clinically ill rescues
animals clinically, radiographically, and reverses abnormal histopathology. We will test DON’s safety and
preliminary efficacy in human pediatric CM. To do so, we will first perform a dose escalation study of DON in
healthy Malawian adults and adults with uncomplicated malaria, evaluating safety. After review, we will
perform a randomized placebo-controlled double-blind safety and preliminary efficacy study of adjunctive DON
in 70 Malawian children with CM. Participants in the first pediatric cohort (n=35) will receive lower doses of
adjunctive DON or placebo. Doses of adjunctive DON administered to the second cohort of pediatric
participants (n=35) will be informed by pharmacokinetic and safety data gathered from those previously
enrolled. Our primary outcome is the proportion of participants with any Grade 3 or severe adverse events
(SAEs). Concurrently with safety studies, DON’s preliminary efficacy in pediatric CM will be evaluated using
brain magnetic resonance imaging (MRI), electroencephalogram (EEG), and transcranial Doppler (TCD). We
hypothesize that Malawian children with CM who receive adjunctive DON will have no increase in mortality or
rates of SAEs compared to participants receiving placebo. We hypothesize that children with CM receiving
adjunctive DON will have biomarker changes (MRI, EEG, TCD) associated with improved outcome.
In summary, this research is significant because the adjunctive therapy, DON, when used in a murine model of
CM, reverses brain swelling, the most important risk factor for death in children with CM. If successful in
subsequent human clinical trials, this would be the first adjunctive therapy with a demonstrable effect on
decreasing death or disability in this patient population. We anticipate that with widespread dissemination of
such a scalable intervention, the public health impact of this devastating infectious disease would finally
decrease.
项目总结/摘要
脑型疟疾(CM)是指恶性疟原虫感染者发生的原因不明的昏迷
寄生虫血症。这种情况很常见,主要影响不到五岁的非洲儿童,
对流行地区的公共卫生产生重大影响。在每年诊断出的约350,000名CM儿童中,15%死亡
30%的幸存者在出院时有神经系统异常。的中流砥柱
治疗是静脉注射抗疟药物和支持性护理。以前没有治疗方法,
已被证明有效降低这种情况下的高死亡率和发病率。我们的长期目标是
建立可行的治疗方法,降低这一弱势群体的死亡率和残疾率。
我们将研究谷氨酰胺拮抗剂6-重氮-5-氧代-L-正亮氨酸(DON)作为候选药物,
治疗小儿CM。我们通过合理的药物发现过程确定了DON并测试了其疗效
在几个临床前研究中。实验性CM小鼠的影像学和病理学异常
类似于在人类儿科CM中观察到的那些; DON给予严重临床疾病抢救的小鼠
动物临床上,放射学,并逆转异常的组织病理学。我们将测试唐的安全性,
在人类儿科CM中的初步疗效。为此,我们将首先进行DON的剂量递增研究,
健康的马拉维成年人和患有单纯性疟疾的成年人,评估安全性。经过审查,我们将
对辅助DON进行随机安慰剂对照双盲安全性和初步疗效研究
在70名马拉维儿童CM。第一个儿科队列的参与者(n=35)将接受较低剂量的
DON或安慰剂。给予第二组儿童的抗DON剂量
参与者(n=35)将被告知从先前研究中收集的药代动力学和安全性数据。
注册了我们的主要结局是发生任何3级或严重不良事件的受试者比例
(SAE)。与安全性研究同时进行的是,DON在儿科CM中的初步疗效将使用以下方法进行评估:
脑磁共振成像(MRI)、脑电图(EEG)和经颅多普勒(TCD)。我们
假设马拉维CM儿童接受预防性DON治疗后死亡率不会增加,
与接受安慰剂的受试者相比的SAE发生率。我们假设接受CM治疗的儿童
持续性DON将具有与改善的结果相关的生物标志物变化(MRI、EEG、TCD)。
总之,这项研究是有意义的,因为连续治疗,DON,当用于小鼠模型,
逆转脑肿胀,脑肿胀是CM儿童死亡的最重要危险因素。如果成功,
在随后的人体临床试验中,这将是第一个对人类具有明显效果的连续疗法。
降低该患者群体的死亡或残疾。我们预计,随着广泛传播
这种可扩展的干预措施,这种毁灭性传染病的公共卫生影响最终将
减少。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Douglas Postels其他文献
Douglas Postels的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Douglas Postels', 18)}}的其他基金
Evaluating EEG as a diagnostic and prognostic biomarker in Malawian children with febrile coma
评估脑电图作为马拉维热昏迷儿童的诊断和预后生物标志物
- 批准号:
10523296 - 财政年份:2023
- 资助金额:
$ 119.42万 - 项目类别:
DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study
DON 在小儿脑型疟疾中的应用:I/II 期剂量递增安全性研究
- 批准号:
10248058 - 财政年份:2021
- 资助金额:
$ 119.42万 - 项目类别:
DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study
DON 在小儿脑型疟疾中的应用:I/II 期剂量递增安全性研究
- 批准号:
10624265 - 财政年份:2021
- 资助金额:
$ 119.42万 - 项目类别:
Viral Co-Infections in Cerebral Malaria: Preparing for Clinical Trials
脑型疟疾的病毒合并感染:为临床试验做准备
- 批准号:
8617351 - 财政年份:2014
- 资助金额:
$ 119.42万 - 项目类别:
Viral Co-Infections in Cerebral Malaria: Preparing for Clinical Trials
脑型疟疾的病毒合并感染:为临床试验做准备
- 批准号:
8824954 - 财政年份:2014
- 资助金额:
$ 119.42万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 119.42万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 119.42万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 119.42万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 119.42万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 119.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 119.42万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 119.42万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 119.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 119.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 119.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)